Original language | English (US) |
---|---|
Pages (from-to) | 285-287 |
Number of pages | 3 |
Journal | JAMA ophthalmology |
Volume | 140 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Funding
ConflictofInterestDisclosures:DrHarperreportedpersonalfeesfromRegeneron. Dr Moshfeghi reported personal fees from Bayer, Novartis, Akebia, and Regeneron, as well as grants from Genentech. No other disclosures were reported.
ASJC Scopus subject areas
- Ophthalmology